secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptevo Therapeutics Inc. (APVO)
CIK:        0001671584
Form:       8-K
Filed at:   2024-03-05T23:59:59+00:00
Accession:  0000950170-24-025427
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptevo reports 2023 net loss of $17.4M; cash $16.9M; AML trial plan announced
-----------------------------------------------------------------------------

- Net loss $17.4M ($1.42/share) vs 2022 net income $8.0M ($1.57/share); cash $16.9M at Dec 31, 2023.
- APVO436 Phase 1b/2 frontline AML trial to start 1H24; interim data expected late 2H24; prior combo showed 91% clinical benefit rate.
- ALG.APV-527 Phase 1 solid tumor trial enrolling; interim results expected 1H24.
- R&D expenses fell to $17.1M (down $0.8M); G&A fell to $11.8M (down $2.1M); $9.65M gain from asset sale.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671584/000095017024025427/0000950170-24-025427-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671584/000095017024025427/apvo-20240305.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-025427

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer